Conformal radiotherapy for hepatocellular carcinoma

Area of Science:

• Hepatobiliary cancers
• Radiation oncology
• Medical physics

Background:

• Technical advancements enable conformal, dose-escalated radiation therapy (RT) for hepatocellular carcinoma (HCC).
• Hepatocellular carcinoma (HCC) often recurs within the liver, necessitating combination treatments.
• Liver toxicity remains a dose-limiting factor in RT for HCC.

Purpose of the Study:

• To review the role of RT in HCC treatment.
• To explore the potential of combining RT with other therapies, such as anti-VEGF agents.
• To highlight the need for further research into RT-induced liver toxicity and clinical trials.

Main Methods:

• Review of existing literature on RT for HCC.
• Analysis of outcomes comparing RT alone, TACE alone, and combined TACE and RT.
• Discussion of RT delivery techniques, fractionation, and toxicity.

Main Results:

• RT alone or combined with TACE shows improved outcomes compared to historical controls or TACE alone.
• RT provides sustained local control for most tumors, but HCC recurrence patterns warrant combination strategies.
• Anti-VEGF agents are of interest due to their activity and radiation-sensitizing properties in HCC.

Conclusions:

• RT is a valuable treatment modality for HCC, offering better outcomes when used alone or with TACE.
• Understanding and mitigating RT-induced liver toxicity is crucial for dose escalation.
• Combining RT with systemic or regional therapies, particularly anti-VEGF agents, holds promise for improving HCC management and warrants randomized trials.